Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | SYK | P43405 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.53 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.53 |
| ▸ | RELA | Q04206 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | FOS | P01100 | 1/20 | 0.53 |
| ▸ | JUN | P05412 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29506595 | 1.00 | MAPT (0.61) | MAPTHPGDMEN1KMT2AALDH1A1 | |
| SCHEMBL5808541 | 0.93 | MEN1 (0.58) | MAPTHPGDMEN1KMT2AALDH1A1 | |
| SCHEMBL18673593 | 0.89 | MAPT (0.51) | MAPTHPGDMEN1KMT2AALDH1A1 | |
| SCHEMBL7017546 | 0.87 | ALDH1A1 (0.54) | MAPTHPGDMEN1KMT2AALDH1A1 | |
| SCHEMBL28456249 | 0.87 | ALDH1A1 (0.58) | MAPTHPGDMEN1KMT2AALDH1A1 | |
| SCHEMBL17181073 | 0.86 | MAPT (0.47) | MAPTHPGDMEN1KMT2AALDH1A1 | |
| SCHEMBL423187 | 0.85 | MEN1 (0.64) | MAPTHPGDMEN1KMT2AALDH1A1 | |
| SCHEMBL29897636 | 0.85 | MEN1 (0.64) | MAPTHPGDMEN1KMT2AALDH1A1 | |
| SCHEMBL21853653 | 0.84 | ALDH1A1 (0.53) | MAPTHPGDMEN1KMT2AALDH1A1 | |
| SCHEMBL1628253 | 0.84 | MEN1 (0.62) | MAPTHPGDMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1834 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109694354-B | Synthesis method of 4-chloro-2-methylthiopyrimidine-5-ethyl formate | 南京哈柏医药科技有限公司 | 2023-10-24 | — | — | CN | claimed |
| CN-112142733-A | Synthetic route of pan FGFR covalent inhibitor PRN1371 | 湖南师范大学 | 2020-12-29 | — | — | CN | claimed |
| WO-2015001567-A1 | PROCESS FOR THE PREPARATION OF (S)-4-[(3-CHLORO-4-METHOXYBENZYL)AMINO]-2-[2- (HYDROXYMETHYL)-1-PYRROLIDINYL]-N-(2-PYRIMIDINYL METHYL-5-PYRIMIDINE CARBOXAMIDE | MSN LABORATORIES PRIVATE LIMITED (IN) | 2015-01-08 | — | — | WO | claimed |
| WO-2004108068-A2 | 4-[4-(4-MORPHOLINO)ANILINO]PYRIMIDINE DERIVATIVES, METHOD FOR PREPARING THEREOF AND ANTIVIRAL PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | B & C BIOPHARM CO., LTD. (KR) | 2004-12-16 | — | — | WO | claimed |
| US-6762189-B1 | HEPATITIS B VIRUS AND HUMAN IMMUNODEFICIENCY VIRUS ANTIPROLIFERATION AGENTS; REDUCED CHANCE OF TOXICITY, SIDE EFFECTS, AND DEVELOPMENT OF RESISTANT VIRAL STRAINS | DONG WHA PHARM. IND. CO., LTD. (KR) | 2004-07-13 | — | — | US | claimed |
| EP-1235806-A4 | NOVEL 5-PYRIMIDINECARBOXAMIDE DERIVATIVES AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING SAID DERIVATIVES | DONG WHA PHARM IND CO LTD (KR) | 2004-02-04 | — | — | EP | claimed |
| EP-1235806-A1 | NOVEL 5-PYRIMIDINECARBOXAMIDE DERIVATIVES AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING SAID DERIVATIVES | DONG WHA PHARMACEUTICAL INDUSTRIAL CO. LTD. (KR) | 2002-09-04 | — | — | EP | claimed |
| WO-2001038308-A1 | NOVEL 5-PYRIMIDINECARBOXAMIDE DERIVATIVES AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING SAID DERIVATIVES | DONG WHA PHARM. IND. CO., LTD (KR) | 2001-05-31 | — | — | WO | claimed |
| US-4129737-A | Process for the preparation of an 8-alkyl-5-oxo-5,8-dihydro-pyrido(2,3-d)pyrimidine-6-carboxylic acid | LABORATOIRE ROGER BELLON (FR) | 1978-12-12 | — | — | US | claimed |
| EP-3478295-B1 | SYNTHESIS OF N-(HETEROARYL)-PYRROLO[3,2-D]PYRIMIDIN-2-AMINES | PHARMACOSMOS HOLDING AS (DK) | 2026-05-27 | — | — | EP | disclosed |
| US-12637461-B2 | Compounds for the activation of AMPK | PFIZER INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-20260137703-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | CANCER RESEARCH TECH LIMITED (GB) | 2026-05-21 | — | — | US | disclosed |
| US-12624032-B2 | Pyrido[2,3-d]pyrimidin-7-ones and related compounds as inhibitors of protein kinases | UNIVERSITY OF HOUSTON SYSTEM (US) | 2026-05-12 | — | — | US | disclosed |
| US-12590098-B2 | Pyrimido pyrimidinone compound and pharmaceutical composition comprising the same | AXCESO BIOPHARMA CO., LTD. (KR) | 2026-03-31 | — | — | US | disclosed |
| US-4233446-A | 5-Chloro-7,8-dihydro-7-oxo-pyrido[2,3-d]pyrimidine-6-carboxylic acid derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 1980-11-11 | — | — | US | disclosed |
| EP-0018139-A2 | Pyrido (2,3-d) pyrimidine derivatives, pharmaceutical compositions containing them and processes for preparing the pyrido (2,3-d) pyrimidine derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 1980-10-29 | — | — | EP | disclosed |
| US-4215216-A | 7,8-Dihydro-2,5,8-trisubstituted-7-oxo-pyrido[2,3-d]pyrimidine-6-carboxylic acid derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 1980-07-29 | — | — | US | disclosed |
| US-4129737-A | Process for the preparation of an 8-alkyl-5-oxo-5,8-dihydro-pyrido(2,3-d)pyrimidine-6-carboxylic acid | LABORATOIRE ROGER BELLON (FR) | 1978-12-12 | — | — | US | disclosed |
| US-4034094-A | 8-Alkyl-5-oxo-5,8-dihydro-pyrido(2,3-d)pyrimidine-6-carboxylic acids for treating urinary tract infections | LABORATOIRE ROGER BELLOW (FR) | 1977-07-05 | — | — | US | disclosed |
| US-3950338-A | BACTERICIDES | LABORATOIRE ROGER BELLON (FR) | 1976-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260137703-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | EGFR, KRAS, O60361 | MAPT 4708/4885HPGD 3204/4885MEN1 3020/4885 |
| US-12637461-B2 | Compounds for the activation of AMPK | PRKAG1, PRKAB1, PRKAA1 | MAPT 4344/4885HPGD 1916/4885MEN1 4306/4885 |
| US-12624032-B2 | Pyrido[2,3-d]pyrimidin-7-ones and related compounds as inhibitors of protein kinases | RIPK2, RIPK1, RIPK4 | MAPT 1893/4885HPGD 3825/4885MEN1 2758/4885 |
| US-12590098-B2 | Pyrimido pyrimidinone compound and pharmaceutical composition comprising the same | PDCD1, CD274, PDCD1LG2 | MAPT 2698/4885HPGD 2553/4885MEN1 715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.